These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23790668)

  • 1. [Genomic signature in breast cancer: Oncotype DX(®)].
    Teig B
    Ann Pathol; 2013 Jun; 33(3):225-8. PubMed ID: 23790668
    [No Abstract]   [Full Text] [Related]  

  • 2. MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
    Lee JY; Won HY; Park JH; Kim HY; Choi HJ; Shin DH; Kang JH; Woo JK; Oh SH; Son T; Choi JW; Kim S; Kim HY; Yi K; Jang KS; Oh YH; Kong G
    J Clin Invest; 2015 May; 125(5):1801-14. PubMed ID: 25822021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Déjà vu for breast cancer two?
    Stearns V; Davidson NE
    J Natl Cancer Inst; 2004 Apr; 96(7):497-9. PubMed ID: 15069104
    [No Abstract]   [Full Text] [Related]  

  • 6. [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].
    Semilgazov VF; Manikhas AG; Semiglazov VV; Bozhok AA; Dashian GA; Ivanov VG; Paltuev RM; Vasil'ev AG; Shchedrin DE; Ermachenkova AM; Nikitina IV; Pen'kov KD; Bessonov AA; Tabagua TT; Kolar'kova VV
    Vopr Onkol; 2011; 57(5):567-77. PubMed ID: 22238925
    [No Abstract]   [Full Text] [Related]  

  • 7. [Breast cancer adjuvants: results of a DUR (drug utilization research) study].
    Nuzzo A
    Suppl Tumori; 2004; 3(4):S86-7. PubMed ID: 15206223
    [No Abstract]   [Full Text] [Related]  

  • 8. Overview of randomized trials of systemic adjuvant therapy.
    Ravdin PM
    Cancer Treat Res; 2000; 103():157-81. PubMed ID: 10948446
    [No Abstract]   [Full Text] [Related]  

  • 9. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
    Carlson JJ; Roth JA
    Breast Cancer Res Treat; 2013 Aug; 141(1):13-22. PubMed ID: 23974828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New European approvals: Alpelisib for HRpos/HER2neg metastatic breast cancer with PIK3CA mutation].
    Corbaux P; Sabatier R
    Bull Cancer; 2020 Oct; 107(10):959-960. PubMed ID: 32977934
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
    Yie SM; Luo B; Ye NY; Xie K; Ye SR
    Clin Exp Metastasis; 2006; 23(5-6):279-89. PubMed ID: 17086357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
    Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
    Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic targeting in breast cancer].
    Penault-Llorca F
    Ann Pathol; 2009 Nov; 29 Spec No 1():S71-3. PubMed ID: 19887259
    [No Abstract]   [Full Text] [Related]  

  • 15. What is the value of the 21 gene recurrence score in HER2-negative patients?
    Rosman M; Mylander WC; Tafra L
    J Clin Oncol; 2010 Nov; 28(31):e647; author reply e648. PubMed ID: 20876423
    [No Abstract]   [Full Text] [Related]  

  • 16. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors.
    Zhang QX; Hilsenbeck SG; Fuqua SA; Borg A
    J Steroid Biochem Mol Biol; 1996 Nov; 59(3-4):251-60. PubMed ID: 9010317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
    Newby JC; Johnston SR; Smith IE; Dowsett M
    Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region].
    Nerich V; Curtit E; Bazan F; Montcuquet P; Villanueva C; Chaigneau L; Cals L; Méneveau N; Dobi E; Altmotlak H; Algros MP; Choulot MJ; Nallet G; Limat S; Mansion S; Pivot X
    Bull Cancer; 2014; 101(7-8):681-9. PubMed ID: 25091650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
    Gori S; Anastasi P; Marrocolo F
    Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.